Ragoo said:

---

Hope you guys got in on the ROKU reversal this morning. It showed a strong reverse h/s pattern. I got the 148c at about 9:30am. Only 2 contracts though.

---

oldarmy1 said:

---

Ragoo said:

---

Hope you guys got in on the ROKU reversal this morning. It showed a strong reverse h/s pattern. I got the 148c at about 9:30am. Only 2 contracts though.

---

You think it can fill that $159.25 gap?

---

UpstateAg said:

---

I would absolutely short BYND right now. It's going down. Like a fake burger to a vegan

---

oldarmy1 said:

---

I'd take ROKU gains off

---

E said:

---

JD and DIS make me sad in pants

---

UpstateAg said:

---

AUPH is halted. Buckle Up. Reason-t!, News Incoming.....

---

UpstateAg said:

---

AUPH is halted. Buckle Up. Reason-t!, News Incoming.....

---

IrishTxAggie said:

---

UpstateAg said:

---

AUPH is halted. Buckle Up. Reason-t!, News Incoming.....

---

Pucker up your booty holes boys and girls. This is how heart attacks happen!

Edit:
ALL ENDPOINTS MET WITH STATISTICAL SIGNIFICANCE

---

Quote:

---

Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
4:05 pm ET December 4, 2019 (BusinessWire) Print
--- Statistically significant results demonstrated in all pre-specified hierarchical secondary endpoints -

--- Aurinia plans to file an NDA submission to the FDA during the first half of 2020 -

--- Company to host conference call to discuss results at 8:30 a.m. ET on Thursday, December 5, 2019 -

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced positive efficacy and safety results from its pivotal AURORA Phase 3 trial of voclosporin, in combination with mycophenolate ("MMF") and low-dose corticosteroids, in the treatment of lupus nephritis ("LN").

"This extraordinary pivotal data confirms voclosporin's ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care," said Neil Solomons, M.D., Chief Medical Officer of Aurinia. "This data represents a significant advance for people living with LN, which can lead to irreversible kidney damage, eventual kidney failure and death."

This global study in which 357 patients with active LN were enrolled, met its primary endpoint of Renal Response rates of 40.8% for voclosporin vs. 22.5% for the control (OR 2.65; p < 0.001). Additionally, all pre-specified hierarchical secondary endpoints achieved statistical significance in favor of voclosporin, which included Renal Response at 24 weeks, Partial Renal Response at 24 and 52 weeks, time to achieve urinary protein-to-creatinine ratio ("UPCR") less-than or equal to 0.5, and time to 50% reduction in UPCR. The robustness of the data was also supported by all pre-specified subgroup analyses (age, sex, race, biopsy class, region, and prior MMF use) favoring voclosporin.

---

Quote:

---

Voclosporin was well tolerated with no unexpected safety signals. Serious adverse events ("SAEs") were reported in 20.8% of voclosporin patients vs. 21.3% in the control arm. Infection was the most commonly reported SAE with 10.1% of voclosporin patients versus 11.2% of patients in the control arm. Overall mortality in the trial was low, with six deaths observed; one in the voclosporin arm and five in the control group. Additionally, the voclosporin arm showed no significant decrease at week 52 in estimated glomerular filtration rate ("eGFR") or increase in blood pressure, lipids or glucose, which are common adverse events associated with legacy calcineurin inhibitors ("CNIs").

"These data represent a potential game changer for patients suffering from this debilitating disease," commented Brad Rovin, MD, FASN, Chief, Division of Nephrology and Medical Director of the Clinical Trials Management Organization at the Ohio State University Wexner Medical Center. "This confirmatory Phase 3 result represents a clinically meaningful leap forward in the treatment of lupus nephritis. Importantly, the data indicate no excess of adverse events in the voclosporin group compared to patients managed with standard of care alone."

Voclosporin was granted Fast Track designation by the FDA in 2016. Aurinia plans to submit an NDA to the FDA in the first half of 2020.

"We are thrilled with the outcomes reported today from the AURORA trial, which unequivocally demonstrate the tremendous potential for voclosporin to play an important role in the treatment of the approximately one million people worldwide living with LN," said Peter Greenleaf, President and Chief Executive Officer of Aurinia. "We are aware of the intense need for a clinically impactful therapy for this serious disease and are working with urgency to complete regulatory filings in the U.S. and worldwide. If approved, we look forward to potentially making voclosporin available to patients beginning in 2021."

"The treatment of lupus nephritis has been extremely challenging to date, and people with lupus are in need of innovative treatments for this serious disease. We're proud to have been part of this important achievement through our work educating people with lupus nephritis about the trial and the importance of clinical trial participation," said Stevan W. Gibson, President and Chief Executive Officer, Lupus Foundation of America. "Voclosporin is the first novel treatment that has demonstrated therapeutic efficacy for people living with lupus nephritis and today marks an important advance in the treatment of this potentially life-threatening disease."

Aurinia expects to present further data from this trial at a future scientific conference in 2020.

Aurinia will host a conference call and webcast to discuss these results tomorrow, Thursday, December 5, 2019 at 8:30 a.m. ET. This event can be accessed on the investor section of the Aurinia website at www.auriniapharma.com.

---